Showing 14 posts of 14 posts found.

NICE recommends Novartis’ previously CDF-exclusive kidney cancer treatment

January 13, 2017
Medical Communications, Sales and Marketing Afinitor, CDF, NICE, Novartis, everolimus

In a reappraisal decision by NICE, everolimus (Novartis’ Afinitor) has been recommended for the treatment of advanced renal cell carcinoma …


EU approval for Eisai kidney cancer treatment

September 15, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, Eisai, Kisplyx, Lenvima, everolimus

The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following …


Eisai partners with Novartis in renal cell carcinoma collaboration

June 3, 2016
Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate

Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …


Eisai submits new cancer combo to EMA for approval

January 12, 2016
Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib

Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …


Bristol-Myers Squibb notches kidney cancer first with Opdivo

September 28, 2015
Research and Development Afinitor, Bristol-Myers Squibb, Kidney cancer, advanced kidney cancer, everolimus, nivolumab, opdivo, renal cell carcinoma

Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is …

NHS backtracks on Cancer Drugs Fund de-listings

March 12, 2015
Sales and Marketing Afinitor, CDF, Cancer Drugs Fund, England, Halaven, NHS, Novartis, everolimus

NHS England is expected to perform a U-turn on several decisions to remove treatments from the cancer drugs fund when …

NHS drops 25 treatments from Cancer Drugs Fund

January 12, 2015
Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus

Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …

Afinitor image

Exclusive: Novartis drug struck off cancer drugs fund

January 8, 2015
Sales and Marketing Afinitor, Jevtana, NHS, NHS England, NICE, Novartis, Sanofi, everolimus

Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …

Afinitor image

Mixed bag for Novartis and Astellas in breast cancer

December 15, 2014
Research and Development, Sales and Marketing Afinitor, Astellas, Novartis, Xtandi, enzalutamide, everolimus

Preliminary results from a Phase II trial of Astellas’ Xtandi (enzalutamide) show positive benefits for the prostate cancer drug when …

novartis image

Another approval for Novartis’ everolimus

February 18, 2013
Sales and Marketing Certican, Novartis, Zortress, everolimus

Novartis has gained US approval for its drug Zortress (everolimus) to prevent liver transplant rejection.Zotress is already used to prevent …


Everolimus approved to treat rare tumour disease

September 8, 2011
Sales and Marketing Novartis, SEGA, Votubia, everolimus

Novartis has gained EU approval for everolimus to be used to treat a rare non-cancerous tumour. Everolimus is already marketed …

Novartis’ Votubia reduces benign brain tumours in SEGA patients

July 11, 2011
Research and Development Novartis, SEGA, Votubia, everolimus

Novartis’ novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus …


Regulators back Novartis’ Votubia

June 28, 2011
Sales and Marketing Novartis, Votubia, everolimus

Novartis’ drug Votubia has been recommended by regulators to treat a disease for which the only current option in Europe …

Novartis’ Afinitor (everolimus)

Novartis fails to sway NICE with Afinitor deal

November 26, 2010
Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus

Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …

Latest content